Back to results

Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a Cdk4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy

Objective

To evaluate the efficacy of giredestrant compared with fulvestrant (both combined with CDK4/6i) in the ESR1m subgroup and FAS

Protocol #

CO44657

Trial Phase:

Phase III

Principal Investigator:

Ross, Masey

Cancer Type
  • Breast
Study Site
  • Virginia Commonwealth University

Age >/=18 years at time of signing Informed Consent Form
Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Lindsey Gwaltney, MS, RN
    Phone: +1 804-628-2112
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: